{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:28:10Z","timestamp":1772720890018,"version":"3.50.1"},"reference-count":111,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Apollo Medical Communications"},{"name":"Scholar Rock, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14737175.2026.2621405","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:12:22Z","timestamp":1769062342000},"page":"211-225","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway"],"prefix":"10.1080","volume":"26","author":[{"given":"Richard S.","family":"Finkel","sequence":"first","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital","place":["Memphis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine","place":["Baltimore, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brown","sequence":"additional","affiliation":[{"name":"Scholar Rock, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhamed","family":"Gueye","sequence":"additional","affiliation":[{"name":"Scholar Rock, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Schroth","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison","place":["Madison, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jena M.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Helen DeVos Children\u2019s Hospital at Spectrum Health","place":["Grand Rapids, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-4061","authenticated-orcid":false,"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[{"name":"University of Oxford","place":["Oxford, UK"]},{"name":"University Hospital of Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914873"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2218549"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00380-8"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddae190"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.180992"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307389100600408"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-102319-103602"},{"key":"e_1_3_5_10_1","unstructured":"Washington University Neuromuscular Disease Center. Spinal muscular atrophy (5q). [cited 2025 Dec 22]. Available from: https:\/\/neuromuscular.wustl.edu\/pathol\/sma.htm#smagen"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00225-X"},{"key":"e_1_3_5_12_1","volume-title":"Annual Cure SMA Research and Clinical Care Meeting","author":"Finkel RS","year":"2024","unstructured":"Finkel RS, Farrar MA, Krosschell KJ, et al. Final safety and efficacy data from the SHINE study in participants with infantile-onset and later-onset SMA. In: Annual Cure SMA Research and Clinical Care Meeting; Austin, (TX), USA; 2024 Jun 5\u20139."},{"key":"e_1_3_5_13_1","volume-title":"Muscular Dystrophy Association (MDA) Clinical and Scientific Conference","author":"Servais L","year":"2025","unstructured":"Servais L, Day JW, Deconinck N, et al. SUNFISH parts 1 and 2: 5-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). In: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; Dallas, (TX), USA; 2025 Mar 16\u201319."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000205144.54457.a3"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-004-0825-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093329"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2012.05.037"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.11.002"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030417"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/joa.12083"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25930"},{"issue":"11","key":"e_1_3_5_22_1","first-page":"1157","article-title":"Spinal muscular atrophy: foetal-like histopathological pattern in Werdnig-Hoffmann disease","volume":"50","author":"Hausmanowa-Petrusewicz I","year":"1974","unstructured":"Hausmanowa-Petrusewicz I, Fidzianska A. Spinal muscular atrophy: foetal-like histopathological pattern in Werdnig-Hoffmann disease. Bull N Y Acad Med. 1974;50(11):1157\u20131172.","journal-title":"Bull N Y Acad Med"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.171878"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr360"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90869-2"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/113.2.433"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03671-x"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12740"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70132"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1044\/2021_AJSLP-20-00217"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2022.04.006"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6871"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01483-7"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.03.004"},{"key":"e_1_3_5_36_1","volume-title":"Muscular Dystrophy Association (MDA) Clinical and Scientific Conference","author":"Waldrop MA","year":"2025","unstructured":"Waldrop MA, Escudero RB, Camarata RA, et al. Long-term follow-up of onasemnogene abeparvovec gene therapy for patients with spinal muscular atrophy type 1 from the START trial. In: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; Dallas, (TX), USA; 2025 Mar 16\u201319."},{"key":"e_1_3_5_37_1","unstructured":"U.S. Food and Drug Administration. FDA approves gene therapy for treatment of SpinalMuscular atrophy Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy"},{"key":"e_1_3_5_38_1","unstructured":"Novartis Pharmaceuticals. Novartis receives FDA approval for itvisma\u00ae the only gene replacement therapy for children two years and older teens and adults with spinal muscular atrophy (SMA). [cited 2026 Jan 9]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04119-2"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04103-w"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/387083a0"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148372"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04408-w"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20524-9"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2534946100"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200011)23:11<1647::AID-MUS1>3.0.CO;2-M"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.876078"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2003832"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.2012.02423.x"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1689-x"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204291200"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200207056"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.09.012"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0811129106"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206410109"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000853"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030533"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040933"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01486-4"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.17987\/jcsm-cr.v2i1.37"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308391"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2020.27.3.151"},{"key":"e_1_3_5_63_1","doi-asserted-by":"crossref","unstructured":"Natarajan H Taimi M Hall S et al. Phase 1 trial in healthy participants of KER-065 a modified activin receptor ligand trap supports development in Duchenne muscular dystrophy and bone disorders. Seattle WA. American Society for Bone and Mineral Research; 2025 Sep 5\u20138.","DOI":"10.1016\/j.nmd.2025.105864"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27222"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-803685-3.00021-5"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125858"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81669-8"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910273"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209151"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.012293"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy382"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01757-z"},{"key":"e_1_3_5_73_1","unstructured":"ClinicalTrials.gov [Internet]. An active treatment study of SRK-015 in patients with type 2 or type 3 spinal muscular atrophy (TOPAZ). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03921528"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16309"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172346"},{"key":"e_1_3_5_76_1","volume-title":"29th Annual Congress of the World Muscle Society","author":"Crawford TO","year":"2024","unstructured":"Crawford TO, De Vivo DC, Krueger JM, et al. Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: results from the 48-month TOPAZ study. In: 29th Annual Congress of the World Muscle Society; Prague, Czechia; 2024 Oct 8\u201312."},{"key":"e_1_3_5_77_1","volume-title":"International Conference of the World Muscle Society","author":"Gueye M","year":"2025","unstructured":"Gueye M, Mazzone ES, Krueger JM, et al. Treatment effects and perceptions among apitegromab-treated patients with type 2\/3 spinal muscular atrophy: patient and caregiver interviews from the TOPAZ clinical trial. In: International Conference of the World Muscle Society; Vienna, Austria; 2025 Oct 7\u201311."},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28311"},{"key":"e_1_3_5_79_1","unstructured":"ClinicalTrials.gov [Internet]. Efficacy and safety of apitegromab in patients with later-onset spinal muscular atrophy treated with nusinersen or risdiplam (SAPPHIRE). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05156320"},{"key":"e_1_3_5_80_1","volume-title":"Annual International Conference of the World Muscle Society","author":"Seferian A","year":"2025","unstructured":"Seferian A, Crawford TO, Servais L, et al. Efficacy and safety of apitegromab in patients aged 13\u201321 years with type 2 or 3 spinal muscular atrophy: outcomes from the SAPPHIRE phase 3 trial. In: Annual International Conference of the World Muscle Society; Vienna, Austria; 2025 Oct 7\u201311."},{"key":"e_1_3_5_81_1","unstructured":"ClinicalTrials.gov [Internet]. Long-term safety and efficacy of apitegromab in patients with SMA who completed previous trials of apitegromab (ONYX). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05626855"},{"key":"e_1_3_5_82_1","unstructured":"ClinicalTrials.gov [Internet]. A study to evaluate how apitegromab works in subjects who are less than 2 years old and have spinal muscular atrophy (OPAL). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07047144"},{"key":"e_1_3_5_83_1","unstructured":"ClinicalTrials.gov [Internet]. EAP of apitegromab for patients with spinal muscular atrophy. [cited 2025 Nov 5]. Available from: http:\/\/clinicaltrials.gov\/study\/NCT06877689"},{"key":"e_1_3_5_84_1","unstructured":"Biohaven Pharmaceuticals Inc. [Internet]. R&D day presentation. 2024 [cited 2025 Nov 18]. Available from: https:\/\/ir.biohaven.com\/static-files\/ba695c23-9f08-4c8b-8cba-330e582ef9af"},{"key":"e_1_3_5_85_1","unstructured":"ClinicalTrials.gov [Internet]. A study to evaluate the efficacy and safety of taldefgrobep alfa in participants with spinal muscular atrophy (RESILIENT). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05337553"},{"key":"e_1_3_5_86_1","unstructured":"Biohaven [Internet]. Biohaven provides update on taldefgrobep alfa development program for spinal muscular atrophy and obesity. [cited 2025 Aug 25]. Available from: https:\/\/ir.biohaven.com\/news-releases\/news-release-details\/biohaven-provides-update-taldefgrobep-alfa-development-program"},{"key":"e_1_3_5_87_1","unstructured":"ClinicalTrials.gov [Internet]. A study to investigate the safety and efficacy of RO7204239 in combination with risdiplam (RO7034067) in participants with spinal muscular atrophy (MANATEE). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05115110"},{"key":"e_1_3_5_88_1","unstructured":"ClinicalTrials.gov [Internet]. A study to evaluate RO7204239 in participants with facioscapulohumeral muscular dystrophy (MANOEUVRE). [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05548556"},{"key":"e_1_3_5_89_1","unstructured":"Cure SMA [Internet]. State of SMA 2023 report 2023. [cited 2025 Sep 23]. Available from: https:\/\/www.curesma.org\/wp-content\/uploads\/2024\/06\/9042024_State-of-SMA_vWeb.pdf"},{"key":"e_1_3_5_90_1","unstructured":"Cure SMA [Internet]. State of SMA 2024 report. [cited 2025 Sep 23]. Available from: https:\/\/www.curesma.org\/wp-content\/uploads\/2025\/04\/State-of-SMA-Report2024_vWeb-4.pdf"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200374"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0790-9"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137311"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.057950"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0613-5"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq329"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/life15071091"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.01.011"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-11-0455"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13121777"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00223.2023"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1419791"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123418"},{"key":"e_1_3_5_104_1","doi-asserted-by":"crossref","unstructured":"Brandsema JF Masson R Proud C et al. Interim results from the ongoing RESPOND study of nusinersen in children with spinal muscular atrophy previously treated with onasemnogene abeparvovec. Orlando FL. MDA Muscular Dystrophy Association; 2024 Mar 3\u20136.","DOI":"10.1016\/j.nmd.2024.07.624"},{"key":"e_1_3_5_105_1","unstructured":"Scholar Rock Inc. [cited 2026 Jan 9]. Available from: https:\/\/scholarrock.com\/"},{"key":"e_1_3_5_106_1","unstructured":"Biohaven Ltd. [cited 2026 Jan 9]. Available from: https:\/\/www.biohaven.com\/"},{"key":"e_1_3_5_107_1","unstructured":"Genentech Inc. [cited 2026 Jan 9]. Available from: https:\/\/www.gene.com\/"},{"key":"e_1_3_5_108_1","unstructured":"Cure SMA [Internet]. [cited 2025 Oct 31]. Available from: https:\/\/curesma.org"},{"key":"e_1_3_5_109_1","unstructured":"SMA Europe [Internet]. [cited 2025 Nov 5]. Available from: https:\/\/www.sma-europe.eu\/"},{"key":"e_1_3_5_110_1","unstructured":"Muscular Dystrophy Association [Internet]. [cited 2025 Oct 31]. Available from: https:\/\/www.mda.org"},{"key":"e_1_3_5_111_1","unstructured":"ClinicalTrials.gov [Internet]. EAP of apitegromab for patients with spinal muscular atrophy. [cited 2025 Sep 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06877689"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nexres.2025.100670"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155655"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2026.2621405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:14:08Z","timestamp":1772716448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2026.2621405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14737175.2026.2621405"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2026.2621405","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}